Face shield + surgical face mask group, N (%) | Surgical face mask group, N (%) | Absolute risk difference | p-valuea | |
---|---|---|---|---|
Intention-to-treat analysis | (N= 141) | (N= 142) | % [95% CI] | |
Primary composite outcome | 1 (0.7) | 3 (2.1) | − 1.40 [− 4.14, 1.33] | 0.31 |
Positive RT-PCR test | 1 (0.7) | 1 (0.7) | 0.005 [− 1.94, 1.96] | 0.74 |
Positive antibody test | ||||
IgG | 0 (0) | 2 (1.4) | − 1.40 [− 3.3, 0.53] | 0.25 |
IgM | 0 (0) | 0 (0) | – | – |
Per protocol analysis | (N= 135) | (N= 140) | % [95% CI] | |
Primary composite outcome | 1 (0.7) | 3 (2.7) | − 1.40 [− 4.20, 1.40] | 0.32 |
Positive RT-PCR test | 1 (0.7) | 1 (0.7) | 0.02 [− 1.98, 2.02] | 0.74 |
Positive antibody test | ||||
IgG | 0 (0) | 2 (1.4) | − 1.40 [− 0.39, 5.37] | 0.25 |
IgM | 0 (0) | 0 (0) | – | – |